Close

Renal cell carcinoma

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Overview

Renal cell carcinoma (RCC, also called hypernephroma, Grawitz tumor, renal adenocarcinoma) is a kidney cancer that arise from the lining of the renal tubule, a portion of the very small tubes in the kidney for filtering the blood and producing the urine. RCC accounts for approximately 90-95% of all kidney cancer cases, which is the most common type of kidney cancer in adults.

Sign and symptom

RCC may keep its clinically mysterious by hiding the symptoms, therefore most patients have developed advanced disease when it is diagnosed. Only 10-15% of patients present the classic triad of flank pain on the side of the body between hip and ribs, hematuria which has red blood cells present in the urine, and flank mass. Other signs and symptoms include weight loss and/or loss of appetite, recurrent fevers, hypertension due to the secretion of renin by the tumor, hypercalcemia, night sweats, malaise and a varicocele which usually occurs at left side caused by the obstruction of the testicular vein.

Loading...
Products
Global Services
Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.